Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Here, doctors explain which COVID-19 vaccine is better when comparing Moderna, Pfizer, and Novovax. Plus, the efficacy of ...

The two companies brought legal action over a repeated sequence in the messenger RNA (mRNA) used in CureVac's patents in life ...

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Pfizer (PFE) discontinues development of experimental RSV therapy sisunatovir from pipeline in a blow for its $525M ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

New COVID-19 vaccines reached about 395,000 New Yorkers, or 3.5%, so far in fall 2024, as health officials push to reverse a trend of limited uptake of the shots despite their proven effectiveness at ...